Healthcare & Life Sciences

Ceptaris

United Statesthirdpointventures.com/companies/ceptaris
acquiredacquired
Sign in to unlockWebsite
acquired
Stage

About

Ceptaris was a specialty pharmaceutical company that developed Valchlor, a proprietary gel formulation of mechlorethamine for treating early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).

Explore Ceptaris's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing